Patients receiving Enbrel (etanercept) in combination with methotrexate for rheumatoid arthritis (RA) are more likely to continue working for longer, according to a new study.

The COMET study, published in Rheumatology, found that active early RA patients receiving the Enbrel-methotrexate combination were nearly three times less likely to stop working compared to patients receiving methotrexate alone, Wyeth Europa said.

Work absenteeism was reduced by almost 50% in the combination group.

The study looked at one-year results which compared the impact of methotrexate alone with methotrexate in combination with Enbrel.